|
| Press Releases |
|
 |
|
| Wednesday, May 21, 2025 |
|
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
| Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2025 年 5 月 30 日から6 月３日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2025 ASCO Annual Meeting）において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
| Friday, May 16, 2025 |
|
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
| Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
| Wednesday, April 30, 2025 |
|
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
| Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
| Friday, April 18, 2025 |
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
| Wednesday, April 16, 2025 |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）が欧州連合（EU）において早期アルツハイマー病の進行を抑制する初めての治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、抗アミロイドベータ（Aβ）モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、欧州委員会（European Commission）より、欧州連合（EU）における販売承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, April 1, 2025 |
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
| Thursday, March 27, 2025 |
|
|
エーザイ、アルツハイマー・パーキンソン病学会において、レカネマブの長期実臨床データやバイオマーカーをはじめとするアルツハイマー病の最新成果を発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗 Aβプロトフィブリル＊抗体レカネマブ（一般名、製品名「レケンビ®」、米国ブランド名「LEQEMBI」）をはじめとする当社のアルツハイマー病（AD）ポートフォリオに関する最新研究成果について、口頭発表６演題を含む合計 16 演題を、4 月 1 日から 5 日までオーストリア・ウィーンおよびバーチャルで開催される「アルツハイマー・パーキンソン病学会において発表することをお知らせします。 more info >> |
|
| Tuesday, March 25, 2025 |
|
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Pet-Food Revolution: Two New Global Surveys Reveal Growing Guardian Openness to Sustainable Diets for Dogs and Cats
Nov 14, 2025 22:00 HKT/SGT
|
|
|
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
|
|
|
Eternal Group at Cosmoprof Asia 2025, The Fragrance Frontier: How Scent is Revolutionizing Spatial Design and the Olfactory Economy
Nov 14, 2025 17:32 HKT/SGT
|
|
|
穎通集團於亞太區美容展2025 揭示香氛跨界空間設計 嗅覺經濟新浪潮
Nov 14, 2025 17:32 HKT/SGT
|
|
|
颖通集团于亚太区美容展2025 揭示香氛跨界空间设计 嗅觉经济新浪潮
Nov 14, 2025 17:32 HKT/SGT
|
|
|
Chuangxin Industries Holdings Limited, a Green Electrolytic Aluminum and Alumina Producer, Announces its Plan to List on the Main Board of the Hong Kong Stock Exchange
Nov 14, 2025 14:14: JST
|
|
|
Chuangxin Industries Holdings Limited, a Green Electrolytic Aluminum and Alumina Producer, Announces its Plan to List on the Main Board of the Hong Kong Stock Exchange
Nov 14, 2025 13:14 HKT/SGT
|
|
|
綠色電解鋁及氧化鋁生產商 創新實業集團有限公司宣佈於香港聯合交易所主板上市計劃
Nov 14, 2025 13:14 HKT/SGT
|
|
|
アリックスパートナーズ、世界のEVバッテリー業界レポートを発表
Nov 14, 2025 11:00: JST
|
|
|
創新實業今起招股 入場費約5550港元
Nov 14, 2025 09:16 HKT/SGT
|
|
|
创新实业今起招股 入场费约5550港元
Nov 14, 2025 09:08 HKT/SGT
|
|
|
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 13, 2025 0:41 JST
|
|
|
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 13, 2025 0:08 JST
|
|
|
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
|
|
|
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
